|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011 (US)
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:eliminationHalfLife
|
5-9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasDrugBankURL
|
https://go.drugbank.com/drugs/DB08868
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMYIE-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPharmacodynamics
|
inhibits free and clot-bound factor Xa
|
|
gptkbp:hasPharmacokinetics
|
rapid absorption, peak plasma concentration in 2-4 hours
|
|
gptkbp:hasSMILES
|
CCOC(=O)C1=CN=C(NC2=CC=CC=C2Cl)N=C1S(=O)(=O)C3=CC=CC=C3O
|
|
gptkbp:hasUNII
|
Y6O7T4G8P9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB08868
|
|
gptkbp:indication
|
prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
treatment and prevention of deep vein thrombosis and pulmonary embolism
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
direct factor Xa inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
gptkb:CYP2J2
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL573
9875401
D08917
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
headache
elevated liver enzymes
dyspepsia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:target
|
gptkb:Factor_Xa
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism
|
|
gptkbp:bfsParent
|
gptkb:Fingolimod
gptkb:fingolimod
|
|
gptkbp:bfsLayer
|
6
|